Richard Aplenc, Ph.D.
Affiliations: | 2011 | University of Pennsylvania, Philadelphia, PA, United States |
Area:
EpidemiologyGoogle:
"Richard Aplenc"Parents
Sign in to add mentor| Timothy Rebbeck | grad student | 2011 | Penn | |
| (Pharmacogenetic and Pharmacogenomic Studies in Pediatric Leukemia.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Abla O, Ries RE, Triche TJ, et al. (2024) Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Advances |
| Cooper TM, Alonzo TA, Tasian SK, et al. (2023) Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. Pediatric Blood & Cancer. e30584 |
| Newman H, Li Y, Liu H, et al. (2022) Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood |
| Pommert L, Cooper TM, Gerbing RB, et al. (2022) Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers. 14 |
| Andolina JR, Wang YC, Ji L, et al. (2022) Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. Bone Marrow Transplantation |
| Rosenfeld E, Getz KD, Miller TP, et al. (2021) Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia. Pediatric Blood & Cancer. e29467 |
| Huang BJ, Smith J, Wang J, et al. (2021) CBFB-MYH11 Fusion Transcripts Distinguish Acute Myeloid Leukemias with Distinct Molecular Landscapes and Outcomes. Blood Advances |
| Getz KD, Alonzo TA, Sung L, et al. (2021) Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood & Cancer. e29313 |
| Brodersen LE, Gerbing RB, Pardo ML, et al. (2020) Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances. 4: 5050-5061 |
| Hoff FW, van Dijk AD, Qiu YH, et al. (2020) Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study. Blood |